FREEDOM, SYNTAX, FAME and FUNCTIONALITY: the future of surgical revascularization in stable ischemic heart disease

T Bruce Ferguson1, Cheng Chen

  • 1East Carolina Heart Institute, Brody School of Medicine at ECU, Greenville, NC, USA.

Future Cardiology
|December 19, 2013
PubMed

Insights

Coronary artery bypass grafting (CABG) has strong evidence for stable ischemic heart disease. However, evolving treatments may impact future CABG referrals, necessitating procedure optimization.

Area of Science:

  • Cardiovascular Surgery
  • Interventional Cardiology
  • Cardiac Surgery

Background:

  • Coronary artery bypass grafting (CABG) is a well-established revascularization procedure for stable ischemic heart disease.
  • Recent evidence from large observational studies and randomized trials strongly supports the efficacy of CABG.
  • The procedure has a robust historical and contemporary evidence base supporting its use.

Purpose of the Study:

  • To evaluate the current evidence supporting coronary artery bypass grafting (CABG) for stable ischemic heart disease.
  • To discuss the impact of the evolving revascularization landscape on future CABG indications.
  • To explore potential modifications and optimizations for CABG in the contemporary medical environment.

Main Methods:

  • Review of large-scale observational database analyses.
  • Analysis of data from recent randomized controlled trials.
  • Discussion of the changing landscape of revascularization therapies.

Main Results:

  • Contemporary evidence strongly supports CABG for stable ischemic heart disease, aligning observational and trial data.
  • The established evidence base for CABG is substantial and historically significant.
  • The evolving field of revascularization presents challenges to the future relevance of current CABG evidence.

Conclusions:

  • Despite robust evidence, the future role of CABG may be influenced by new revascularization techniques.
  • Optimization and modification of CABG procedures are crucial for its continued application.
  • The article discusses strategies for adapting CABG to the evolving treatment landscape for ischemic heart disease.

Related Concept Videos

Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.8K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
655
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
2.1K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
943